Brian Wong, M.D., Ph.D.

Money Moves

Leading company through acquisition

For decades, the 27 million American adults and children with food allergies had one option: avoid the allergen and carry an EpiPen. That changed in February 2024 when the FDA approved Xolair as the first drug to reduce allergic reactions—including anaphylaxis—from accidental exposure to multiple foods. Now GSK has paid $2.2 billion for RAPT Therapeutics and its experimental antibody ozureprubart, betting it can build a better version with once-quarterly dosing instead of Xolair's every-two-to-four-week schedule.

Updated Jan 20